over-year decreas cyclophosphamid sale associ headwind
oper margin investor seem skittish compon outlook
view highli contain issu could prove conserv
bax revenu -- oper report basi
respect -- match revenu estim along consensu forecast renal
sale larg line forecast share
street sale came compar
consensu estim forecast ip sale vs
consensu expect approxim flat oper basi
year year partli due impact attribut hurrican maria
total hurrican impact quarter mirror guidanc surgic sale
vs estim consensu sale total
vs consensu project gross margin
compar street us weigh hurrican sale
effect neg impact foreign exchang meanwhil oper margin
compar us street reflect declin year
year nevertheless higher-than-expect incom slightli lower tax rate
vs assumpt help drive adjust ep beat target
consensu forecast estim hurrican maria reduc sale
total ep
full-year target constant-curr revenu growth
forecast compani report revenu guidanc impli
revenu slightli ahead street project
meaning initi target key assumpt compani
outlook includ favor currenc sale impact hurrican maria
affect clari sale vs cyclophosphamid
sale compar ep forecast rang
compar street estim initi assumpt
bax revenu guidanc suggest total sale line
street repres flat perform oper basi
aforement hurrican impact compani guid ep vs
consensu cyclo impact assum face one two entrant
seem rais concern repres op margin headwind
drive modest expect oper margin progress
believ prudent give guidanc fashion base unknown cyclo
note compani still intend updat project beyond
may believ signal above-consensu margin progress continu
pleas see page report import disclosur
compani split allow baxter better focu deliv margin expans
top bottom line growth opportun longer term new baxter
hamper low singl digit top line growth trajectori lower oper
ebitda margin profil rel peer earli go clearer path forward
abl acceler top line growth better expect margin expans
opportun could bolster long-term outlook given top-lin margin profil
new baxter believ compani deserv trade premium med tech peer
current valuat keep us market perform
increment share gain sigma
spectrum pump new pd cycler
product updat arti
theranova prismax prismalung
transform bolster
om expans start
level
oper cash flow expect grow
new tuck-in bolt-on acquisit
expect gener top-lin
gambro margin synergi deliv
improv ahead expect
om ebitda margin expans
opportun realiz sooner
pipelin opportun acquisit
deliv greater expect top-lin
contribut next year
gambro margin synergi fail
meet key benchmark improv
om expans come
pipelin fail deliv
 fail deliv new top-lin
diversifi global healthcar compani develop medic
devic product use hospit kidney dialysi center nurs home rehabilit
center clinic medic research laboratori patient in-hom use
biopharma solut also chronic acut product offer renal
divis gener total revenu medic product sale
complet acquisit gambro ab largest acquisit histori
bolster renal busi product portfolio juli spun bioscienc
divis form baxalta acquir shire
renal includ periton dialysi in-cent hemodialysi renal
therapi servic compani anticip growth constant currenc
basi medic deliveri includ sale bax iv therapi infus pump
administr set drug reconstitut devic compani project sale
growth compris premix oncolog drug platform
inhal anesthesia critic care product pharmaci compound servic
forecast flat sale due sale occur arent
expect repeat well increas competit nutrit previous part
ip compani anticip sale growth constant currenc basi
advanc surgeri sale product hemostasi tissu seal adhes prevent
project increas year year acut therapi
includ bax crrt portfolio organ support product grow
lastli categori larg contract manufactur servic
expect low single-digit sale declin benefit custom stockpil order
see lower manufactur revenu shire note
sale guidanc doesnt includ contribut product recent acquir
deal still track close first half year respect
cash flow anticip gener oper cash flow roughli
capital-expenditure free cash flow approxim
clari acquisit slate add sale strengthen bax
presenc gener pharmaceut space indic pipelin impact
gener clari start play alongsid organ growth
initi like sigma spectrum platform new crrt machin new hemofiltr
devic theranova advanc develop product two
new trial addit compani recent launch updat iter oxiri
membran use prismaflex system manag sepsi product
help filter remov excess level cytokin endotoxin inflammatori
mediat patient blood repres mean augment bax presenc
acut renal market importantli continu believ enhanc intern
program high-growth compani capac deal
rang like pursu smaller tuck-in acquisit like recent move
product addit know manag priorit invest
money back compani growth also pursu regular stock buyback
stock bought last year come manag current
plan buy-back expect approxim base
varianc impos bax intern valuat model
respect revenu bax lrp sale compound-annual-growth-rate assumpt given compani
product pipelin see growth rate improv recogn
possibl reach compani clearli indic growth
trajectori acceler move past product discontinu
cyclo headwind give credenc view incom statement
compani project adjust oper margin stress
view peak oper margin addit help mix
innov time bax gross margin estim aid
focu drive cost save improv manufactur network project
adjust ep accret assum clari
compani look oper cash flow roughli expect
capital-expenditure see free cash flow year set valuat argument
asid believ feasibl long-term project reduc invest risk
associ stock make outlook attract rel peer struggl
even full-year guidanc receiv favor updat beyond
outlook upcom may bax next investor day
rais price target new target appli unchang
valuat multipl new ep ebitda estim respect
averag result
figur baxter result vs cowen estim consensu
compani report thomson eikon cowen compani
chg medic good gross gross total expens incom incom tax incom tax incom oper ex intang incom non-controlling inc inc oper ex-intang estim cowen
compani report thomson eikon cowen compani
year end decemb end decemb end decemb medic good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recur gain incom non-controlling intang amort inc inc oper ex-intang cowen
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
compani specif risk includ impact long-act factor viii agent
global share advat franchis limit increas plasma fraction
capac ig franchis time regulatori approv hyq line-extens
bioscienc product develop realiz synergi impact margin
gambro acquisit acquisit exposur emerg market
